Merck Agrees With ADAP Crisis Task Force to Provide Access to HIV Treatment Idvynso
MT Newswires Live
Yesterday
Merck (MRK) said Monday it agreed with the ADAP Crisis Task Force to help state AIDS Drug Assistance Programs provide access to its once-daily HIV treatment Idvynso for eligible individuals.
The US Food and Drug Administration approved Idvynso in April as a single-tablet regimen containing 100 milligrams of doravirine and 0.25 mg of islatravir for the treatment of HIV-1 infection in adults, the company said.
Merck said state AIDS Drug Assistance Programs supported more than 250,000 people living with HIV in the US in 2024.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.